{"content":"<li class=\"n-box-item date-title\" data-end=\"1386133199\" data-start=\"1386046800\" data-txt=\"Friday, December 20, 2019\">Tuesday, December  3, 2013</li><li class=\"n-box-item sa-box-item\" data-id=\"1444121\" data-ts=\"1386112154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWRE\" target=\"_blank\">GWRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1444121-guidewire-issues-largely-in-line-guidance-shares-plus-5_6-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guidewire issues largely in-line guidance, shares +5.6% AH</a></h4><ul>\n<li>Guidewire (NYSE:<a href=\"https://seekingalpha.com/symbol/GWRE\" title=\"Guidewire Software, Inc.\">GWRE</a>) has used its FQ1 CC to <a href=\"http://blogs.barrons.com/techtraderdaily/2013/12/03/guidewire-rising-fyq1-rev-eps-beat/\" target=\"_blank\">guide</a> for FQ2 revenue of $76M-$78M and EPS of $0.00-$0.02 (consensus is at $77M and $0.05), and FY14 (ends July '14) revenue of $330.5M-$342.5M and EPS of $0.20-$0.25 (consensus is at $336.9M and $0.25).</li>\n<li>Guidewire's license revenue (drives future services revenue) fell 9% Y/Y to $18.9M, and equaled 28% of total revenue.However, the insurance software firm's deferred revenue balance rose 6% Q/Q to $43.5M.</li>\n<li>Aggressive spending continues to pressure EPS: R&amp;D spend rose 27% Y/Y to $18.8M, and sales/marketing spend rose 38% to $17.1M.</li>\n<li>\n<a href=\"https://seekingalpha.com/currents/post/1443711\" target=\"_blank\">FQ1 results</a>, PR</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1444121\" data-linked=\"Guidewire issues largely in-line guidance, shares +5.6% AH\" data-tweet=\"$GWRE - Guidewire issues largely in-line guidance, shares +5.6% AH https://seekingalpha.com/news/1444121-guidewire-issues-largely-in-line-guidance-shares-plus-5_6-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1444121-guidewire-issues-largely-in-line-guidance-shares-plus-5_6-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1444051\" data-ts=\"1386110302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1444051-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx'>CCXI</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/GWRE' title='Guidewire Software, Inc.'>GWRE</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/NSPH' title='Nanosphere, Inc.'>NSPH</a> <font color='green'>+3%</font>. <a href='https://seekingalpha.com/symbol/DSGX' title='Descartes Systems Group Inc. &#40;The&#41;'>DSGX</a> <font color='green'>+2%</font>.</li><li><b>Top losers<b>, as of 5:15 p.m.</b>:</b> <a href='https://seekingalpha.com/symbol/OVTI' title='OmniVision Technologies, Inc.'>OVTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ACMP' title='Access Midstream Partners, L.P.'>ACMP</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/OMED' title='OncoMed Pharmaceuticals, Inc'>OMED</a> <font color='red'>-4%</font>. <a href='https://seekingalpha.com/symbol/UTI' title='Universal Technical Institute'>UTI</a> <font color='red'>-3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1444051\" data-linked=\"After-hours Gainers / Losers\" data-tweet=\"$CCXI $JCP $GWRE - After-hours Gainers / Losers https://seekingalpha.com/news/1444051-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1444051-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1444011\" data-ts=\"1386109891\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCR\" target=\"_blank\">NCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1444011-ncr-closes-lower-following-acquisitions-synergies-growth-prospects-in-focus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCR closes lower following acquisitions; synergies, growth prospects in focus</a></h4><ul>\n<li>NCR's (<a href=\"https://seekingalpha.com/symbol/NCR\" title=\"NCR Corporation\">NCR</a> <font color=\"red\">-2.7%</font>) <a href=\"https://seekingalpha.com/currents/post/1441021\" target=\"_blank\">$1.65B acquisition</a> of Digital Insight will help the company conceal its \"inability to grow EPS 14-18% organically as guided,\" says <a href=\"http://www.streetinsider.com/Analyst+Comments/NCR+Corp.+%28NCR%29+Digital+Insight+Deal+Helps+Conceals+Low+Organic+Growth+-+Analyst/8943223.html\" target=\"_blank\">Wedbush</a>, which is reiterating a Neutral.</li>\n<li>The firm also questions NCR's ability to cross-sell Digital's online/mobile banking software, and thinks it paid a steep price (16x EBITDA), especially since Intuit (NASDAQ:<a href=\"https://seekingalpha.com/symbol/INTU\" title=\"Intuit Inc.\">INTU</a>) sold Digital to Thoma Bravo for just $1.025B <a href=\"https://seekingalpha.com/currents/post/1114772\" target=\"_blank\">a few months ago</a>. But it's worth noting <a href=\"http://finance.fortune.cnn.com/2013/12/03/thoma-bravo-digital-insight/\" target=\"_blank\">sources tell </a><em><a href=\"http://finance.fortune.cnn.com/2013/12/03/thoma-bravo-digital-insight/\" target=\"_blank\">Fortune</a> </em>intuit was forced to sell low due to the fact it was \"intent on selling Digital Insight at warp speed.\"</li>\n<li>\n<a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4125181/update-compass-point-upgrades-ncr-following-acquisition-\" target=\"_blank\">Compass Point</a>, which has upgraded NCR to Buy, is more positive. It sees the acquisitions of both Digital Insight and Alaric Systems improving NCR's financial service growth and margin profile, and notes NCR's business mix now looks \"much more like major financial technology players such as Fiserv and FIS Global as compared to legacy competitor Diebold.\"</li>\n<li>Industry analyst <a href=\"http://www.americanbanker.com/issues/178_231/digital-insight-purchase-a-timely-move-for-ncr-1064020-1.html\" target=\"_blank\">David Albertazzi</a> likes how the deal expands NCR's multi-channel banking reach, given how many transactions have \"migrated out of [bank] branches,\" and thinks ATM could use Digital Insight to create services relying on both ATMs and mobile apps.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1444011\" data-linked=\"NCR closes lower following acquisitions; synergies, growth prospects in focus\" data-tweet=\"$NCR $NCR $INTU - NCR closes lower following acquisitions; synergies, growth prospects in focus https://seekingalpha.com/news/1444011-ncr-closes-lower-following-acquisitions-synergies-growth-prospects-in-focus?source=tweet\" data-url=\"https://seekingalpha.com/news/1444011-ncr-closes-lower-following-acquisitions-synergies-growth-prospects-in-focus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443981\" data-ts=\"1386109153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBI\" target=\"_blank\">AMBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443981-ambit-hit-hard-after-quizartinib-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambit hit hard after quizartinib news</a></h4><ul>\n<li>Ambit Biosciences (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AMBI\" title=\"Ambit Biosciences Corp\">AMBI</a>) comes off a halt and promptly drops<font color=\"red\"> </font><strong><font color=\"red\">37%</font></strong>.</li>\n<li>For more, see: ABMI <a href=\"https://seekingalpha.com/currents/post/1443751\" target=\"_blank\">will not seek accelerated approval</a> for quizartinib based on Phase 2 data</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443981\" data-linked=\"Ambit hit hard after quizartinib news\" data-tweet=\"$AMBI - Ambit hit hard after quizartinib news https://seekingalpha.com/news/1443981-ambit-hit-hard-after-quizartinib-news?source=tweet\" data-url=\"https://seekingalpha.com/news/1443981-ambit-hit-hard-after-quizartinib-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443961\" data-ts=\"1386108907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAS\" target=\"_blank\">OAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443961-oasis-petroleum-in-7m-share-public-offering-minus-3_1-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oasis Petroleum in 7M-share public offering, -3.1% AH</a></h4><ul>\n<li>Oasis Petroleum (NYSE:<a href=\"https://seekingalpha.com/symbol/OAS\" title=\"Oasis Petroleum Inc.\">OAS</a>) <font color=\"red\">-3.1%</font> AH after announcing a public offering of   7M shares of common stock.</li>\n<li>OAS intends to use the net proceeds to pay down debt and for general corporate  purposes.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443961\" data-linked=\"Oasis Petroleum in 7M-share public offering, -3.1% AH\" data-tweet=\"$OAS - Oasis Petroleum in 7M-share public offering, -3.1% AH https://seekingalpha.com/news/1443961-oasis-petroleum-in-7m-share-public-offering-minus-3_1-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1443961-oasis-petroleum-in-7m-share-public-offering-minus-3_1-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443891\" data-ts=\"1386107542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OVTI\" target=\"_blank\">OVTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443891-omnivisions-guidance-disappoints-shares-minus-13_7-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OmniVision&#39;s guidance disappoints, shares -13.7% AH</a></h4><ul>\n<li>Though OmniVision's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OVTI\" title=\"OmniVision Technologies, Inc.\">OVTI</a>) FQ2 results beat estimates, the image sensor vendor is guiding for FQ3 revenue of $310M-$340M and EPS of $0.28-$0.44. That's largely below a consensus of $399.9M and $0.43. (PR)</li>\n<li>OmniVision notes its saw slowing smartphone market growth in FQ2 - <a href=\"http://www.idc.com/getdoc.jsp?containerId=prUS24418013\" target=\"_blank\">IDC estimates</a> calendar Q3 shipments rose 39% Y/Y, albeit with a mix shift towards cheaper phones - as well as \"intensifying competition.\" The company has been battling not only with age-old rival Sony (Apple's other iPhone image sensor supplier), but also <a href=\"https://seekingalpha.com/currents/post/1298852\" target=\"_blank\">Samsung</a> and low-end upstarts such as Himax (<a href=\"https://seekingalpha.com/symbol/HIMX\" title=\"Himax Technologies, Inc.\">HIMX</a> - <a href=\"https://seekingalpha.com/currents/post/1395112\" target=\"_blank\">previous</a>).</li>\n<li>FQ2 gross margin was 18.8%, +140 bps Q/Q and +220 bps Y/Y. In addition, cost controls resulted in opex falling 2% Y/Y to $49.9M (12.5% of revenue).</li>\n<li>OmniVision's cash balance rose by $25.1M Q/Q to $265.6M.(equal to 35% of its current market cap). With shares depressed, could the company end up deploying some of that cash in a new buyback? OmniVision hasn't announced one <a href=\"http://www.prnewswire.com/news-releases/omnivision-revises-second-quarter-fiscal-2012-revenues-guidance-133351473.html\" target=\"_blank\">since 2011</a>.</li>\n<li>\n<a href=\"http://www.media-server.com/m/p/68n46akg\" target=\"_blank\">CC</a> at 5PM ET. <a href=\"https://seekingalpha.com/currents/post/1443781\" target=\"_blank\">FQ2 results</a>, PR.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443891\" data-linked=\"OmniVision&#39;s guidance disappoints, shares -13.7% AH\" data-tweet=\"$OVTI $OVTI $HIMX - OmniVision&#39;s guidance disappoints, shares -13.7% AH https://seekingalpha.com/news/1443891-omnivisions-guidance-disappoints-shares-minus-13_7-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1443891-omnivisions-guidance-disappoints-shares-minus-13_7-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443841\" data-ts=\"1386106484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCXI\" target=\"_blank\">CCXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443841-chemocentryx-rallies-on-ccx168-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChemoCentryx rallies on CCX168 data</a></h4><ul>\n<li>ChemoCentryx (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CCXI\" title=\"ChemoCentryx\">CCXI</a>) is out with top-line data from a Phase 2 study of CCX168 in ANCA-associated AARV.<br>\n</li>\n<li>In short, the company says the results demonstrate \"that CCX168 appears to be safe, well tolerated and successful in  allowing both reduction and elimination of high-dose corticosteroids,  part of standard of care for AARV patients, without compromising  efficacy or safety during a 12-week treatment period.\"</li>\n<li>The data (at 12 weeks): CCX168 plus CYC plus low-dose steroids, renal remission 75%, urinary MCP-1, -72%; CCX168 plus CYC plus no steroids, renal remission 63%, urinary MCP-1, -52%; SOC, renal remission 44%, urinary MCP-1, -37%. (PR)</li>\n<li>CCXI <font color=\"green\">+6.5%</font> AH</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443841\" data-linked=\"ChemoCentryx rallies on CCX168 data\" data-tweet=\"$CCXI - ChemoCentryx rallies on CCX168 data https://seekingalpha.com/news/1443841-chemocentryx-rallies-on-ccx168-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1443841-chemocentryx-rallies-on-ccx168-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443811\" data-ts=\"1386106143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACMP\" target=\"_blank\">ACMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443811-access-midstream-partners-in-6m-unit-secondary-offering-minus-1_7-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Access Midstream Partners in 6M-unit secondary offering, -1.7% AH</a></h4><ul>\n<li>Access Midstream Partners (NYSE:<a href=\"https://seekingalpha.com/symbol/ACMP\" title=\"Access Midstream Partners, L.P.\">ACMP</a>) <font color=\"red\">-1.7%</font> AH after announcing a secondary public offering of 6M common units representing limited partner interests owned by Global  Infrastructure  Partners II.</li>\n<li>ACMP will receive no proceeds from the offering,  and the number of outstanding common units  will remain unchanged.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443811\" data-linked=\"Access Midstream Partners in 6M-unit secondary offering, -1.7% AH\" data-tweet=\"$ACMP - Access Midstream Partners in 6M-unit secondary offering, -1.7% AH https://seekingalpha.com/news/1443811-access-midstream-partners-in-6m-unit-secondary-offering-minus-1_7-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1443811-access-midstream-partners-in-6m-unit-secondary-offering-minus-1_7-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443761\" data-ts=\"1386105928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAEX\" target=\"_blank\">SAEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443761-saexploration-awarded-40m-in-contacts-jumps-8_4-percent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SAExploration awarded $40M in contacts; jumps 8.4%</a></h4><ul>\n<li>SAExploration (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SAEX\" title=\"SAExploration Holdings, Inc.\">SAEX</a>) <font color=\"green\">skies 8.4%</font> after winning contracts for work in Alaska and Brazil totaling about $40M. The Brazil operations are expected to begin in Q2 and Alaska in Q3.</li>\n<li>Kudos to SA Pro's Carbondale Capital <a href=\"https://seekingalpha.com/article/1855261-saexploration-buy-at-a-discount-to-crescendo-partners-and-joel-greenblatt-110-upside\" target=\"_blank\">who two weeks ago</a> called the decline in the stock due to a number of project delays a buying opportunity.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443761\" data-linked=\"SAExploration awarded $40M in contacts; jumps 8.4%\" data-tweet=\"$SAEX - SAExploration awarded $40M in contacts; jumps 8.4% https://seekingalpha.com/news/1443761-saexploration-awarded-40m-in-contacts-jumps-8_4-percent?source=tweet\" data-url=\"https://seekingalpha.com/news/1443761-saexploration-awarded-40m-in-contacts-jumps-8_4-percent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443681\" data-ts=\"1386105168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443681-celldex-to-offer-shares-stock-falls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celldex to offer shares, stock falls</a></h4><ul>\n<li>Celldex Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLDX\" title=\"Celldex Therapeutics, Inc\">CLDX</a>) announces a 6.5M share public offering. (PR)</li>\n<li>CLDX <font color=\"red\">-2%</font> AH</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443681\" data-linked=\"Celldex to offer shares, stock falls\" data-tweet=\"$CLDX - Celldex to offer shares, stock falls https://seekingalpha.com/news/1443681-celldex-to-offer-shares-stock-falls?source=tweet\" data-url=\"https://seekingalpha.com/news/1443681-celldex-to-offer-shares-stock-falls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443511\" data-ts=\"1386103796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443511-truck-stocks-retreat-after-industry-report-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Truck stocks retreat after industry report disappoints</a></h4><ul> <li>Shares of Navistar (<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='red'>-2.3%</font>), Paccar (<a href='https://seekingalpha.com/symbol/PCAR' title='PACCAR Inc.'>PCAR</a> <font color='red'>-1.6%</font>), and Cummins (<a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a> <font color='red'>-2.2%</font>)&nbsp;are skittish after <a href=\"http://article.wn.com/view/2013/12/03/US_Class_8_Truck_Fleet_Rises_3_to_FourYear_High_Polk_Reports/#/related_news\" target=\"_blank\">Class 8 truck orders</a> for November comes in lower than expectations.</li> <li>Valuation on the trio of heavy duty truck sellers is seen as stretched out by some analysts.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1443511\" data-linked=\"Truck stocks retreat after industry report disappoints\" data-tweet=\"$NAV $NAV $PCAR - Truck stocks retreat after industry report disappoints https://seekingalpha.com/news/1443511-truck-stocks-retreat-after-industry-report-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/1443511-truck-stocks-retreat-after-industry-report-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443491\" data-ts=\"1386103577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPVD\" target=\"_blank\">MPVD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443491-mountain-province-diamonds-says-permit-okd-for-gahcho-kue-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mountain Province Diamonds says permit OKd for Gahcho Kue mine</a></h4><ul>     <li>De Beers Canada and Mountain Province Diamonds (MDM <font color=\"green\">+8.9%</font>) say the  Mackenzie Valley Land and Water Board approved a pioneer land use permit for the Gahcho Kue diamond mine, which will allow land-based site works to begin in preparation for deliveries planned for the 2014 winter road season.</li>     <li>Gahcho Kue is expected to mine ~31M metric tons of ore containing ~49M carats.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1443491\" data-linked=\"Mountain Province Diamonds says permit OKd for Gahcho Kue mine\" data-tweet=\"$MPVD - Mountain Province Diamonds says permit OKd for Gahcho Kue mine https://seekingalpha.com/news/1443491-mountain-province-diamonds-says-permit-okd-for-gahcho-kue-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/1443491-mountain-province-diamonds-says-permit-okd-for-gahcho-kue-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443441\" data-ts=\"1386102689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443441-sanofi-lower-after-presenting-new-u300-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi lower after presenting new U300 data</a></h4><ul>\n<li>Sanofi (<a href=\"https://seekingalpha.com/symbol/SNY\" title=\"Sanofi\">SNY</a> <font color=\"red\">-2.5%</font>) trades lower on the session after the company presented data on U300, an improved version of Lantus which the company hopes can take the edge off the latter's looming patent expiration.</li>\n<li>SNY says the drug was more effective than Lantus at controlling low blood sugar. Here's <em>FierceBiotech</em>: \"The headline SNY <a href=\"http://www.fiercebiotech.com/story/sanofi-touts-promising-phiii-data-next-gen-diabetes-therapy-rivals-circle/2013-12-03\" target=\"_blank\">was looking for</a> today centers on a 23% drop in the  number of patients suffering from ... hypoglycemia when  compared to the Lantus arm.\"</li>\n<li>U300 also \"<a href=\"http://www.reuters.com/article/2013/12/03/us-sanofi-diabetes-idUSBRE9B205M20131203\" target=\"_blank\">met its goal</a> in three other Phase III clinical  trials, showing similar blood sugar level control as Lantus in patients  with type 2 diabetes not previously treated with insulin and  uncontrolled on oral medication, as well as in patients with type 1  diabetes already treated with insulin,\" Reuters notes.<br>\n</li>\n<li>Nevertheless, U300 apparently missed the endpoint in one Phase 3 trial with  insulin-naïve patients.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443441\" data-linked=\"Sanofi lower after presenting new U300 data\" data-tweet=\"$SNY - Sanofi lower after presenting new U300 data https://seekingalpha.com/news/1443441-sanofi-lower-after-presenting-new-u300-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1443441-sanofi-lower-after-presenting-new-u300-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443361\" data-ts=\"1386100372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGHT\" target=\"_blank\">EGHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443361-8x8-lower-after-voicenet-acquisition-cc-lower-margins-mentioned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">8x8 lower after Voicenet acquisition CC; lower margins mentioned</a></h4><ul>\n<li>During a CC (<a href=\"https://seekingalpha.com/article/1873781-8x8s-ceo-presents-at-acquisition-of-voicenet-solutions-conference-transcript?part=single\" target=\"_blank\">transcript</a>) discussing the company's <a href=\"https://seekingalpha.com/currents/post/1403132\" target=\"_blank\">$18.4M acquisition</a> of U.K. hosted VoIP services firm Voicenet, 8x8 (<a href=\"https://seekingalpha.com/symbol/EGHT\" title=\"8X8 Inc\">EGHT</a> <font color=\"red\">-4.2%</font>) mentioned Voicenet currently has a gross margin of ~40%. That's well below the 71.4% GM 8x8 reported for calendar Q3.</li>\n<li>Altogether, Voicenet's lower GM will is expected to reduce 8x8's total GM by 200-300 bps starting in FQ4 (the March '14 quarter),</li>\n<li>Nonetheless, 8x8 expects Voicenet's margins will match those of the rest of the company in 18-24 months, as it eliminates the reselling of low-margin services such as broadband connectivity, and does away with lease financing agreements.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443361\" data-linked=\"8x8 lower after Voicenet acquisition CC; lower margins mentioned\" data-tweet=\"$EGHT - 8x8 lower after Voicenet acquisition CC; lower margins mentioned https://seekingalpha.com/news/1443361-8x8-lower-after-voicenet-acquisition-cc-lower-margins-mentioned?source=tweet\" data-url=\"https://seekingalpha.com/news/1443361-8x8-lower-after-voicenet-acquisition-cc-lower-margins-mentioned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443351\" data-ts=\"1386099826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FST\" target=\"_blank\">FST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443351-forest-oil-minus-6-percent-following-2014-capex-and-cost-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forest Oil -6% following 2014 capex and cost guidance</a></h4><ul>     <li>Forest Oil (<a href=\"https://seekingalpha.com/symbol/FST\" title=\"Forest Oil Corporation\">FST</a> <font color=\"red\">-6.1%</font>) is maintained with a <a href=\"http://www.streetinsider.com/Analyst+Comments/Forest+Oil+%28FST%29+Remains+Sell-Rated+at+Goldman+Following+2014+Guidance/8943091.html\" target=\"_blank\">Sell rating</a> at Goldman Sachs following the company's 2014 capital budget and guidance.</li>     <li>Goldman says production guidance of 120M-130M cfe/day was in line with its expectations, 2014 capex of $290M-$310M was slightly higher than expected, and cash and non-cash operating costs were higher than expected.</li>     <li>The scope for resource improvement in the Eagle Ford to take growth and  rates of return to a higher level is key for greater credit, but with capex slightly higher and cash costs higher than expected, the firm continues to see sub-par corporate return on cash invested and ongoing free cash deficits.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1443351\" data-linked=\"Forest Oil -6% following 2014 capex and cost guidance\" data-tweet=\"$FST - Forest Oil -6% following 2014 capex and cost guidance https://seekingalpha.com/news/1443351-forest-oil-minus-6-percent-following-2014-capex-and-cost-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/1443351-forest-oil-minus-6-percent-following-2014-capex-and-cost-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443301\" data-ts=\"1386098854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RSLS\" target=\"_blank\">RSLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443301-enteromedics-may-be-post-approval-takeout-target-northland\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnteroMedics may be post-approval takeout target: Northland</a></h4><ul>\n<li>Shares of EnteroMedics (ETRM <font color=\"green\">+45.3%</font>) are holding onto this morning's <a href=\"https://seekingalpha.com/currents/post/1442751\" target=\"_blank\">big gains</a> \u2014 and then some.<br>\n</li>\n<li>Count Northland Capital's Suraj Kalia among those who think the stock has <a href=\"http://www.streetinsider.com/Rumors/Analyst+Sees+Another+300%25%2B+Upside+in+EnteroMedics+%28ETRM%29+on+Positive+18+Month+Data/8942647.html\" target=\"_blank\">further to run</a>.</li>\n<li>\"Based on the current 18-month data, and barring any unforeseen kinks in  any subgroup analysis (only top-line data has been released so far), we  do not envision a mixed or negative ruling in an FDA panel,\" Kalia says, referencing the pivotal <a href=\"https://seekingalpha.com/currents/search?query=VBLOC\" target=\"_blank\">VBLOC</a> study. <br>\n</li>\n<li>Northland's target is $7 and although Kalia says that the firm \"can articulate on DCF's as to how [the] price target was achieved ... ETRM could now be a good takeout target post-approval.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443301\" data-linked=\"EnteroMedics may be post-approval takeout target: Northland\" data-tweet=\"$RSLS - EnteroMedics may be post-approval takeout target: Northland https://seekingalpha.com/news/1443301-enteromedics-may-be-post-approval-takeout-target-northland?source=tweet\" data-url=\"https://seekingalpha.com/news/1443301-enteromedics-may-be-post-approval-takeout-target-northland\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443291\" data-ts=\"1386098698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCPIQ\" target=\"_blank\">MCPIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443291-molycorp-turns-green-as-ceo-sees-positive-cash-flow-by-late-2014-early-2015\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molycorp turns green as CEO sees positive cash flow by late 2014/early 2015</a></h4><ul>     <li>Molycorp (MCP <font color=\"green\">+2.8%</font>) shares pop higher on heavy volume as Swiss publication <em>Finanz und Wirtschaft</em> features an <a href=\"http://www.fuw.ch/article/die-preise-mussen-effizient-werden/\" target=\"_blank\">interview</a> with CEO Constantine Karayannopoulos, who says the company will be cash flow positive by the end of 2014 or the beginning of 2015.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1443291\" data-linked=\"Molycorp turns green as CEO sees positive cash flow by late 2014/early 2015\" data-tweet=\"$MCPIQ - Molycorp turns green as CEO sees positive cash flow by late 2014/early 2015 https://seekingalpha.com/news/1443291-molycorp-turns-green-as-ceo-sees-positive-cash-flow-by-late-2014-early-2015?source=tweet\" data-url=\"https://seekingalpha.com/news/1443291-molycorp-turns-green-as-ceo-sees-positive-cash-flow-by-late-2014-early-2015\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443281\" data-ts=\"1386098157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKS\" target=\"_blank\">AKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443281-ak-steel-praises-favorable-itc-ruling-in-steel-trade-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AK Steel praises favorable ITC ruling in steel trade case</a></h4><ul>     <li>The U.S. International Trade Commission <a href=\"http://www.usitc.gov/press_room/news_release/2013/er1202ll1.htm\" target=\"_blank\">ruled in favor</a> of AK Steel (<a href=\"https://seekingalpha.com/symbol/AKS\" title=\"AK Steel Holding Corp\">AKS</a> <font color=\"green\">+2.7%</font>) yesterday in an anti-dumping and countervailing trade petition against allegedly cut-priced imports of non-oriented electrical steel from six countries.</li>     <li>AKS praises the ruling which said the trading practices were causing injury; the preliminary injury determination means that cases against the foreign producers will proceed.</li>     <li>Earlier, BofA <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4124127/update-bank-of-america-upgrades-ak-steel-on-better-pensi\" target=\"_blank\">upgraded</a> shares to Neutral from Underperform after adjusting estimated 2013 underfunded legacy liabilities for a better equity return and higher discount rate.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443281\" data-linked=\"AK Steel praises favorable ITC ruling in steel trade case\" data-tweet=\"$AKS - AK Steel praises favorable ITC ruling in steel trade case https://seekingalpha.com/news/1443281-ak-steel-praises-favorable-itc-ruling-in-steel-trade-case?source=tweet\" data-url=\"https://seekingalpha.com/news/1443281-ak-steel-praises-favorable-itc-ruling-in-steel-trade-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443261\" data-ts=\"1386097920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443261-micron-rallies-as-needham-issues-buy-rating-predicts-margin-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron rallies as Needham issues Buy rating, predicts margin growth</a></h4><ul>\n<li>Needham's <a href=\"http://blogs.barrons.com/techtraderdaily/2013/12/03/micron-needham-starts-at-buy-on-structural-dram-nand-change-lessons-from-hdd/\" target=\"_blank\">Rajvindra Gill</a> has launched coverage on Micron (<a href=\"https://seekingalpha.com/symbol/MU\" title=\"Micron Technology Inc.\">MU</a> <font color=\"green\">+1.8%</font>) with a Buy and $30 PT, while asserting the DRAM/NAND flash vendor could see its gross margin eventually rise to 40% from a current ~30%.</li>\n<li>Gill points out rising estimates (aided by the Elpida deal) have led Micron's forward P/E (based on FY15 estimates) to fall to 9 from a July level of 15, in spite of <a href=\"https://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1385586000000&amp;chddm=40194&amp;chls=IntervalBasedLine&amp;q=NASDAQ:MU&amp;ntsp=1&amp;ei=qiqeUoCUI4KSiQLiuAE\" target=\"_blank\">the ongoing rally</a> seen by its shares. He argues Micron should trade at 12x-14x EPS and 3x-4x its tangible book value.</li>\n<li>Echoing <a href=\"https://seekingalpha.com/currents/post/1426571\" target=\"_blank\">David Einhorn</a> and others, Gill declares the newly consolidated DRAM industry is \"entering a period of rationality that will focus on [ROIC] as opposed to market share or survival.\" He also expects the lion's share of DRAM and NAND capex to be directed towards technology upgrades rather than capacity investments. Micron set a market-pleasing <a href=\"https://seekingalpha.com/currents/post/1212672\" target=\"_blank\">FY14 capex budget</a> of $2.6B-$3.2B in July.</li>\n<li>Margin improvements are expected to be driven not only by supply controls, but by a <a href=\"https://seekingalpha.com/currents/post/1438231\" target=\"_blank\">NAND mix shif</a>t towards SSDs and cost cuts at Elpida.</li>\n<li>Also: 1) <a href=\"http://www.digitimes.com/news/a20131202PD203.html\" target=\"_blank\">Digitimes reports</a> SK Hynix (<a href=\"https://seekingalpha.com/symbol/HXSCL\" title=\"SK Hynix, Inc.\">OTC:HXSCL</a>), still dealing with the fallout from <a href=\"https://seekingalpha.com/currents/post/1259582\" target=\"_blank\">a massive fire</a> at a Chinese fab, is unable to meet demand from its PC OEM clients. 2) <a href=\"http://www.digitimes.com/news/a20131203VL200.html\" target=\"_blank\">DRAMeXchange reports</a> PC DRAM contract prices ticked higher in 2H November, and are likely to be flat or up in December.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443261\" data-linked=\"Micron rallies as Needham issues Buy rating, predicts margin growth\" data-tweet=\"$MU $MU $HXSCL - Micron rallies as Needham issues Buy rating, predicts margin growth https://seekingalpha.com/news/1443261-micron-rallies-as-needham-issues-buy-rating-predicts-margin-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/1443261-micron-rallies-as-needham-issues-buy-rating-predicts-margin-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443211\" data-ts=\"1386096996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNIS\" target=\"_blank\">UNIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443211-cantor-raises-target-on-unilife-after-novartis-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor raises target on Unilife after Novartis deal</a></h4><ul>\n<li>\"Novartis now joins Sanofi, Medimmune (AstraZeneca), and Hikma, which have entered into long-term deals,\" Cantor's Jeremy Feffer says, <a href=\"http://www.streetinsider.com/Analyst+Comments/Unilife+Corporation+%28UNIS%29+Target+Raised+to+%248+at+Cantor+Fitzgerald/8942489.html\" target=\"_blank\">reiterating</a> a Buy rating on shares of Unilife (<a href=\"https://seekingalpha.com/symbol/UNIS\" title=\"Unilife Corporation\">UNIS</a> <font color=\"green\">+14%</font>).</li>\n<li>Feffer says that although UNIS \"is unlikely to finalize the 10-12 agreements management  initially expected to sign in 2013 ... the size, scope, and  diversity of the deals announced thus far significantly enhance  management's credibility.\"</li>\n<li>Price target lifted to $8 from $6.</li>\n<li>See also: UNIS <a href=\"https://seekingalpha.com/currents/post/1441311\" target=\"_blank\">strikes</a> supply agreement with Novartis</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443211\" data-linked=\"Cantor raises target on Unilife after Novartis deal\" data-tweet=\"$UNIS - Cantor raises target on Unilife after Novartis deal https://seekingalpha.com/news/1443211-cantor-raises-target-on-unilife-after-novartis-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/1443211-cantor-raises-target-on-unilife-after-novartis-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443181\" data-ts=\"1386096295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSBC\" target=\"_blank\">HSBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443181-hsbc-loses-buy-rating-at-nomura\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HSBC loses Buy rating at Nomura</a></h4><ul>\n<li>HSBC (<a href=\"https://seekingalpha.com/symbol/HSBC\" title=\"HSBC Holdings PLC\">HSBC</a> <font color=\"red\">-1%</font>) is the downside outlier in a green U.K. banking sector after Nomura downgrades to Hold.</li>\n<li>In other U.K. banking news, <a href=\"https://seekingalpha.com/symbol/RBS\" title=\"The Royal Bank of Scotland Group plc\">RBS</a> is forced to<a href=\"http://www.bloomberg.com/news/2013-12-03/rbs-apologizes-to-customers-for-latest-cashpoint-failure.html\" target=\"_blank\"> issue an apology</a> for another technical glitch which left customers unable to access their accounts through ATMs, or pay for purchases with debit cards.</li>\n<li>CEO Hester: \"Last night\u2019s systems failure was unacceptable ... For decades, RBS failed to invest properly in its systems. It will take time, but we are investing heavily in building IT systems our customers can rely on.\u201d</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443181\" data-linked=\"HSBC loses Buy rating at Nomura\" data-tweet=\"$HSBC $HSBC $RBS - HSBC loses Buy rating at Nomura https://seekingalpha.com/news/1443181-hsbc-loses-buy-rating-at-nomura?source=tweet\" data-url=\"https://seekingalpha.com/news/1443181-hsbc-loses-buy-rating-at-nomura\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443171\" data-ts=\"1386096063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLED\" target=\"_blank\">OLED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443171-universal-display-slumps-following-muddy-waters-rumor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Universal Display slumps following Muddy Waters rumor</a></h4><ul><li><a href=\"https://twitter.com/OptionCast/status/407941320578064385\" target=\"_blank\">A rumor</a> that Muddy Waters is about to issue a bearish report on Universal Display (<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='red'>-3.2%</font>) has led shares to sell off in afternoon trading.</li><li>Shares fell two weeks ago due to an <a href=\"https://seekingalpha.com/currents/post/1428531\" target=\"_blank\">adverse EPO ruling</a>, but remain soundly above where they traded before Universal posted a <a href=\"https://seekingalpha.com/currents/post/1398572\" target=\"_blank\">strong Q3 beat</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1443171\" data-linked=\"Universal Display slumps following Muddy Waters rumor\" data-tweet=\"$OLED - Universal Display slumps following Muddy Waters rumor https://seekingalpha.com/news/1443171-universal-display-slumps-following-muddy-waters-rumor?source=tweet\" data-url=\"https://seekingalpha.com/news/1443171-universal-display-slumps-following-muddy-waters-rumor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443161\" data-ts=\"1386096049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443161-herbalife-rallies-as-belgian-appeals-court-overturns-pyramid-scheme-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife rallies as Belgian appeals court overturns pyramid scheme ruling</a></h4><ul>\n<li>Herbalife (<a href=\"https://seekingalpha.com/symbol/HLF\" title=\"Herbalife Ltd.\">HLF</a> <font color=\"green\">+4.6%</font>) bulls get (more) good news this afternoon as a Belgian appeals court has apparently overturned a previous ruling that found the company was in operation of an pyramid scheme.</li>\n<li>The company says it has \"always believed that the first judgment contained factual       errors and was based on misinterpretations of its direct-selling sales       method, and was confident that the original judgment would be overturned       on appeal.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443161\" data-linked=\"Herbalife rallies as Belgian appeals court overturns pyramid scheme ruling\" data-tweet=\"$HLF - Herbalife rallies as Belgian appeals court overturns pyramid scheme ruling https://seekingalpha.com/news/1443161-herbalife-rallies-as-belgian-appeals-court-overturns-pyramid-scheme-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/1443161-herbalife-rallies-as-belgian-appeals-court-overturns-pyramid-scheme-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443151\" data-ts=\"1386095700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BDSI\" target=\"_blank\">BDSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443151-biodelivery-sciences-hires-vp-of-sales-stock-adds-to-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioDelivery Sciences hires VP of sales, stock adds to gains</a></h4><ul>\n<li>With today's gains, shares of BioDelivery Sciences (<a href=\"https://seekingalpha.com/symbol/BDSI\" title=\"BioDelivery Sciences International, Inc.\">BDSI</a> <font color=\"green\">+8.5%</font>) are up nearly <font color=\"green\">12%</font> this week.</li>\n<li>On Monday, the company said that a Phase 3 trial of Clonidine Topical Gel (in PDN) will go ahead in Q1 2014 after a \"positive meeting\" with the FDA. (PR)</li>\n<li>Today, the company announced a new VP of sales and managed markets, David Acheson.</li>\n<li>Among other duties, Acheson will \"oversee the sales and managed markets support behind the anticipated launch of <a href=\"https://seekingalpha.com/currents/search?query=bunavail\" target=\"_blank\">Bunavail</a> in 2014.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443151\" data-linked=\"BioDelivery Sciences hires VP of sales, stock adds to gains\" data-tweet=\"$BDSI - BioDelivery Sciences hires VP of sales, stock adds to gains https://seekingalpha.com/news/1443151-biodelivery-sciences-hires-vp-of-sales-stock-adds-to-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/1443151-biodelivery-sciences-hires-vp-of-sales-stock-adds-to-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443141\" data-ts=\"1386095518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMT\" target=\"_blank\">CAMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443141-camtek-slides-sa-article-calls-shares-grossly-overvalued\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Camtek slides, SA article calls shares &quot;grossly overvalued&quot;</a></h4><ul>\n<li>Camtek (<a href=\"https://seekingalpha.com/symbol/CAMT\" title=\"Camtek Ltd.\">CAMT</a> <font color=\"red\">-16%</font>) shares slide, potentially on a <a href=\"https://seekingalpha.com/article/1873991-camtek-significantly-overvalued-due-to-hype-has-2-50-price-target\" target=\"_blank\">bearish article</a> by SA contributor 3D Analytics which argues that the company is \"grossly overvalued\" when compared to its peer's multiples and analyst targets.</li>\n<li>\"GreenJet does not manufacture PCBs. Instead, it applies solder mask onto a PCB.\" This confusion has buoyed the stock by lumping it into the 3D market hype, the author claims. A similar point was <a href=\"https://seekingalpha.com/article/1871771-camtek-untangling-the-3-d-printing-story\" target=\"_blank\">hashed out in detail</a> by Jonathan Fishman yesterday, although he believes the technology still has a $700M potential target market and would provide significant operational savings to customers.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443141\" data-linked=\"Camtek slides, SA article calls shares &quot;grossly overvalued&quot;\" data-tweet=\"$CAMT - Camtek slides, SA article calls shares &quot;grossly overvalued&quot; https://seekingalpha.com/news/1443141-camtek-slides-sa-article-calls-shares-grossly-overvalued?source=tweet\" data-url=\"https://seekingalpha.com/news/1443141-camtek-slides-sa-article-calls-shares-grossly-overvalued\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443071\" data-ts=\"1386094120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443071-pdl-biopharma-slips-article-sees-big-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDL BioPharma slips, article sees big downside</a></h4><ul><li>PDL BioPharma (<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='red'>-13.3%</font>)&nbsp;is having a tough session, down double-digits on nearly double its 10-day average volume.</li><li>Perhaps helping to tip sentiment is SA contributor Ruerd Heeg, who says \"the stock seems to be <a href=\"https://seekingalpha.com/article/1872451-pdl-biopharma-is-severely-overvalued\" target=\"_blank\">significantly overvalued</a> with more than 30% downside under extremely optimistic assumptions.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"1443071\" data-linked=\"PDL BioPharma slips, article sees big downside\" data-tweet=\"$PDLI - PDL BioPharma slips, article sees big downside https://seekingalpha.com/news/1443071-pdl-biopharma-slips-article-sees-big-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/1443071-pdl-biopharma-slips-article-sees-big-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1443061\" data-ts=\"1386094112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUNEQ\" target=\"_blank\">SUNEQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1443061-sunedison-rallies-after-announcing-new-fund-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunEdison rallies after announcing new fund investment</a></h4><ul>\n<li>DeLange Landen Financial Services (DLL) is doubling its investment in a SunEdison (SUNE <font color=\"green\">+1.9%</font>) fund meant to finance new solar installations (via sale/leaseback agreements) to $100M. Projects enabled by the fund are expected to be completed in 2013. (PR)</li>\n<li>Much like <a href=\"https://seekingalpha.com/currents/post/1414292\" target=\"_blank\">SolarCity</a>, SunEdison is looking to use asset-based financing options to grow its U.S. solar installation business. Thanks in part to healthy subsidies, domestic demand has <a href=\"http://cleantechnica.com/2013/09/18/us-solar-installations-surged-quarter-2-2013/\" target=\"_blank\">grown rapidly in 2013</a>.</li>\n<li>News of the investment comes a week after SunEdison said it's planning to <a href=\"https://seekingalpha.com/currents/post/1431511\" target=\"_blank\">sell a 20%-30% stake</a> in a solar project subsidiary through a U.S. IPO.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1443061\" data-linked=\"SunEdison rallies after announcing new fund investment\" data-tweet=\"$SUNEQ - SunEdison rallies after announcing new fund investment https://seekingalpha.com/news/1443061-sunedison-rallies-after-announcing-new-fund-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/1443061-sunedison-rallies-after-announcing-new-fund-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442991\" data-ts=\"1386092890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECTE\" target=\"_blank\">ECTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442991-echo-therapeutics-falls-further-after-announcing-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Echo Therapeutics falls further after announcing offering</a></h4><ul>\n<li>The <a href=\"https://seekingalpha.com/currents/post/1441981\" target=\"_blank\">premarket sell-off</a> in shares of Echo Therapeutics (<a href=\"https://seekingalpha.com/symbol/ECTE\" title=\"Echo Therapeutics\">OTC:ECTE</a> <font color=\"red\">-17.8%</font>) accelerated meaningfully into the regular session \u2014 the stock is now off double-digits.</li>\n<li>Investors are apparently unhappy about an offering of stock and warrants.</li>\n<li>Not helping matters is SA contributor Nick Zheng, who \"<a href=\"https://seekingalpha.com/article/1873251-symphony-cgm-system-may-not-accurately-detect-glucose-levels\" target=\"_blank\">doubts</a> the Symphony CGM system will be used in EU hospitals even if/when ECTE receives a CE mark.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442991\" data-linked=\"Echo Therapeutics falls further after announcing offering\" data-tweet=\"$ECTE - Echo Therapeutics falls further after announcing offering https://seekingalpha.com/news/1442991-echo-therapeutics-falls-further-after-announcing-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/1442991-echo-therapeutics-falls-further-after-announcing-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442981\" data-ts=\"1386092777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442981-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Top 10 Gainers:</b> <a href='https://seekingalpha.com/symbol/OMED' title='OncoMed Pharmaceuticals, Inc'>OMED</a> <font color='green'>+125%</font>. ETRM <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/REX' title='REX American Resources Corporation'>REX</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/BAXS' title='Baxano Surgical, Inc.'>BAXS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/UNIS' title='Unilife Corporation'>UNIS</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/INS' title='Intelligent Systems Corp'>INS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ICLD-OLD' title='InterCloud Systems, Inc.'>ICLD</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/IDSA' title='Industrial Services of America, Inc.'>IDSA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+12%</font>.</li><li><b>Top 10 Losers:</b> <a href='https://seekingalpha.com/symbol/KKD' title='Krispy Kreme Doughnuts, Inc.'>KKD</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ECTE' title='Echo Therapeutics'>OTC:ECTE</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/YRCW' title='YRC Worldwide, Inc.'>YRCW</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/CAMT' title='Camtek Ltd.'>CAMT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SYUT' title='Synutra International, Inc.'>SYUT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/LDOS' title='Leidos Holdings, Inc.'>LDOS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AZC' title='Augusta Resource Corporation'>AZC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MBIS' title='Mediabistro Inc.'>MBIS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442981\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$OMED $RSLS $REX - Midday Gainers / Losers https://seekingalpha.com/news/1442981-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1442981-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442961\" data-ts=\"1386092129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERF\" target=\"_blank\">ERF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442961-enerplus-raises-production-guidance-shares-plus-3-percent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enerplus raises production guidance, shares +3%</a></h4><ul>     <li>Enerplus (<a href=\"https://seekingalpha.com/symbol/ERF\" title=\"Enerplus Corporation\">ERF</a> <font color=\"green\">+3%</font>) <a href=\"http://finance.yahoo.com/news/enerplus-increases-2013-production-estimate-221000123.html\" target=\"_blank\">raises its 2013 production  forecast</a> to 89K boe/day from 87.5K boe/day, based on strong operational performance during October and November which tracks for Q4 production volume of ~92K boe/day due primarily to higher natural gas production.</li>     <li>Based upon 2014 planned capital spending of $760M (up 11% Y/Y), ERF forecasts production of 96K-100K boe/day, a 10% Y/Y increase; ERF expects 2014 production at Fort Berthold will increase by ~15%, driving light crude oil volumes to represent 67% of total oil production.</li>\n<li>BMO <a href=\"http://www.streetinsider.com/Upgrades/BMO+Capital+Upgrades+Enerplus+%28ERF%29+to+Outperform/8940828.html\" target=\"_blank\">upgrades</a> shares to Outperform from Market Perform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442961\" data-linked=\"Enerplus raises production guidance, shares +3%\" data-tweet=\"$ERF - Enerplus raises production guidance, shares +3% https://seekingalpha.com/news/1442961-enerplus-raises-production-guidance-shares-plus-3-percent?source=tweet\" data-url=\"https://seekingalpha.com/news/1442961-enerplus-raises-production-guidance-shares-plus-3-percent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442941\" data-ts=\"1386091443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QEP\" target=\"_blank\">QEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442941-qep-resources-plus-2-percent-on-plans-to-separate-midstream-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QEP Resources +2% on plans to separate midstream business</a></h4><ul>     <li>QEP Resources' (<a href=\"https://seekingalpha.com/symbol/QEP\" title=\"QEP Resources, Inc.\">QEP</a> <font color=\"green\">+2.1%</font>) announcement that it will <a href=\"https://seekingalpha.com/currents/post/1441011\" target=\"_blank\">pursue a separation of its midstream business</a> and its interest in QEP Midstream Partners (<a href=\"https://seekingalpha.com/symbol/QEPM\" title=\"QEP Midstream Partners, LP\">QEPM</a> <font color=\"green\">+2%</font>) did not specify how it would be achieved, but Sterne Agee thinks it will happen through an IPO or an outright sale of the field services company and the interest in QEPM.</li>     <li>There's a <a href=\"http://247wallst.com/energy-business/2013/12/03/qep-resources-yields-to-activist-investor/\" target=\"_blank\">lot of room for growth</a> in the midstream limited partnership, where incentive distribution rights kick in after a distribution of $0.2875 to limited partners, Sterne says; in Q3, the partnership distributed just $0.13.</li>     <li>The firm also raises its price target on QEP to $39 from $36, based on a sum-of-the-parts estimated value.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442941\" data-linked=\"QEP Resources +2% on plans to separate midstream business\" data-tweet=\"$QEP $QEP $QEPM - QEP Resources +2% on plans to separate midstream business https://seekingalpha.com/news/1442941-qep-resources-plus-2-percent-on-plans-to-separate-midstream-business?source=tweet\" data-url=\"https://seekingalpha.com/news/1442941-qep-resources-plus-2-percent-on-plans-to-separate-midstream-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442931\" data-ts=\"1386091049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442931-3d-systems-turns-negative-after-tilson-makes-short-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D Systems turns negative after Tilson makes short case</a></h4><ul><li>\"DDD is one of so many unbelievably great shorts out there right now.,\" says <a href=\"http://blogs.barrons.com/techtraderdaily/2013/12/03/3-d-systems-one-of-the-great-shorts-in-market-of-massive-stupidity-says-tilson/\" target=\"_blank\">Whitney Tilson</a> in his latest note. His comments have led 3D Systems (<a href='https://seekingalpha.com/symbol/DDD' title='3D Systems Corp.'>DDD</a> <font color='red'>-0.8%</font>) to turn negative, after initially trading higher in response to <a href=\"https://seekingalpha.com/currents/post/1441431\" target=\"_blank\">FBR's coverage launch</a>.</li><li>Tilson criticizes 3D's multiples - shares trade at 17x trailing sales, 64x EBITDA, and 63x 2014E EPS - and calls the company a better short than it was when <a href=\"https://seekingalpha.com/currents/post/829121\" target=\"_blank\">Citron Research</a> declared it one, given a 26% rally and (in Tilson's view) deteriorating fundamentals. 3D <a href=\"https://seekingalpha.com/currents/post/1364562\" target=\"_blank\">recently raised</a> its 2013 revenue guidance, but lowered its EPS guidance due to aggressive spending plans.</li><li>The talkative hedge fund manager admits he has \"sure taken my lumps on the short side recently,\" but nonetheless calls the current market \"the best environment to find great shorts since March 2000 (even better than Oct. 2007).&rdquo;</li></ul><div class=\"tiny-share-widget\" data-id=\"1442931\" data-linked=\"3D Systems turns negative after Tilson makes short case\" data-tweet=\"$DDD - 3D Systems turns negative after Tilson makes short case https://seekingalpha.com/news/1442931-3d-systems-turns-negative-after-tilson-makes-short-case?source=tweet\" data-url=\"https://seekingalpha.com/news/1442931-3d-systems-turns-negative-after-tilson-makes-short-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442911\" data-ts=\"1386090062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLR\" target=\"_blank\">DLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442911-data-center-owners-sell-off-following-google-cloud-infrastructure-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data center owners sell off following Google cloud infrastructure launch</a></h4><ul>\n<li>Data center owners Digital Realty (<a href=\"https://seekingalpha.com/symbol/DLR\" title=\"Digital Realty Trust, Inc.\">DLR</a> <font color=\"red\">-4.2%</font>), CoreSite (<a href=\"https://seekingalpha.com/symbol/COR\" title=\"CoreSite Realty Corporation\">COR</a> <font color=\"red\">-4%</font>), and (to a lesser extent) DuPont Fabros (<a href=\"https://seekingalpha.com/symbol/DFT\" title=\"DuPont Fabros Technology\">DFT</a> <font color=\"red\">-1.1%</font>) have joined Rackspace, Amazon, and Equnix (<a href=\"https://seekingalpha.com/currents/post/1442771\" target=\"_blank\">previous</a>) in selling off after Google <a href=\"https://seekingalpha.com/currents/post/1441521\" target=\"_blank\">officially launched</a> its Compute Engine cloud infrastructure (IaaS) platform (the service was in beta until now), and simultaneously unveiled new features and major price cuts.</li>\n<li>While data center colocation services firms don't directly compete with IaaS providers, they're indirectly affected to the extent customers migrate workloads away from their own servers (hosted within colocation facilities) to IaaS platforms that often leverage data centers built by the service providers themselves.</li>\n<li>However, colocation providers do offer <a href=\"http://www.telecomramblings.com/2013/10/coresite-equinix-level-3-line-amazons-aws-direct-connect/\" target=\"_blank\">connectivity services</a> for linking client servers with IaaS platforms such as Amazon Web Services.</li>\n<li>Synergy Research <a href=\"https://seekingalpha.com/currents/post/1436111\" target=\"_blank\">recently estimated</a> the traditional Web hosting market only grew 3% Y/Y in Q3, while the IaaS and cloud app platform (PaaS) markets collectively grew 46%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442911\" data-linked=\"Data center owners sell off following Google cloud infrastructure launch\" data-tweet=\"$DLR $DLR $COR - Data center owners sell off following Google cloud infrastructure launch https://seekingalpha.com/news/1442911-data-center-owners-sell-off-following-google-cloud-infrastructure-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/1442911-data-center-owners-sell-off-following-google-cloud-infrastructure-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442871\" data-ts=\"1386089274\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CWEI\" target=\"_blank\">CWEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442871-clayton-williams-plus-5_5-percent-on-global-hunter-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clayton Williams +5.5% on Global Hunter upgrade</a></h4><ul>     <li>Clayton Williams Energy (<a href=\"https://seekingalpha.com/symbol/CWEI\" title=\"Clayton Williams Energy, Inc.\">CWEI</a> <font color=\"green\">+5.5%</font>) is <a href=\"http://www.streetinsider.com/Upgrades/UPDATE%3A+Global+Hunter+Securities+Raises+Clayton+Williams+Energy+%28CWEI%29+to+Buy/8941007.html\" target=\"_blank\">upgraded to Buy</a> from Neutral with a $100 price target, raised from $82, at Global Hunter, which cites CWEI's core position in the Permian's Southern Delaware Wolfcamp play.</li>\n<li>The firm's belief is that the euphoria that swept over the Central/Northern Midland Basin in 2013 will soon emerge as a major theme in the Southern Delaware Basin, which could prove a sizable catalyst for CWEI.</li>\n<li>CWEI also has emerged as a top M&amp;A target for companies looking to break into the Permian or expand upon a current position given the upside potential and attractive valuation, the firm adds.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442871\" data-linked=\"Clayton Williams +5.5% on Global Hunter upgrade\" data-tweet=\"$CWEI - Clayton Williams +5.5% on Global Hunter upgrade https://seekingalpha.com/news/1442871-clayton-williams-plus-5_5-percent-on-global-hunter-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1442871-clayton-williams-plus-5_5-percent-on-global-hunter-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442841\" data-ts=\"1386088311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVBD\" target=\"_blank\">RVBD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442841-riverbed-sales-chief-leaves-for-fusion-io\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Riverbed sales chief leaves for Fusion-io</a></h4><ul>\n<li>Ian Whiting, who was hired only <a href=\"https://seekingalpha.com/currents/post/553461\" target=\"_blank\">15 months ago</a> to be Riverbed's (<a href=\"https://seekingalpha.com/symbol/RVBD\" title=\"Riverbed Technology, Inc.\">RVBD</a> <font color=\"green\">+0.1%</font>) sales chief (he previously worked at Brocade), is now leaving the WAN optimization hardware vendor to become Fusion-io's (<a href=\"https://seekingalpha.com/symbol/FIO\" title=\"Fusion-io, Inc.\">FIO</a> <font color=\"red\">-5%</font>) sales chief. (PR)</li>\n<li>The hiring comes less than two months after Fusion-io <a href=\"https://seekingalpha.com/currents/post/1350152\" target=\"_blank\">announced the departure</a> of its last sales chief, James Dawson, in tandem with an FQ1 report that feature <a href=\"https://seekingalpha.com/currents/post/1349032\" target=\"_blank\">very weak guidance</a>.</li>\n<li>Whiting joins a company that has seen <a href=\"https://seekingalpha.com/currents/post/1009001\" target=\"_blank\">major C-suite changes</a> this year, and is trying to ramp its enterprise server flash module sales to offset declining orders from top customers Apple and Facebook.</li>\n<li>Fusion-io is still looking for a replacement for CFO Dennis Wolf, whose resignation was announced at the same time as Dawson's.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442841\" data-linked=\"Riverbed sales chief leaves for Fusion-io\" data-tweet=\"$RVBD $RVBD $FIO - Riverbed sales chief leaves for Fusion-io https://seekingalpha.com/news/1442841-riverbed-sales-chief-leaves-for-fusion-io?source=tweet\" data-url=\"https://seekingalpha.com/news/1442841-riverbed-sales-chief-leaves-for-fusion-io\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442821\" data-ts=\"1386088190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMO\" target=\"_blank\">BMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442821-canadian-banks-slip-after-bmo-kicks-off-fq4-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian banks slip after BMO kicks off FQ4 earnings</a></h4><ul>\n<li>The <a href=\"https://seekingalpha.com/currents/post/1441831\" target=\"_blank\">headlines </a>for Bank of Montreal's (<a href=\"https://seekingalpha.com/symbol/BMO\" title=\"Bank of Montreal\">BMO</a> <font color=\"red\">-4.7%</font>) results say \"beat,\" but RBC calls it a <a href=\"https://twitter.com/amberkanwar/status/407866112705974272\" target=\"_blank\">big miss</a> after stripping out a $0.19 <a href=\"https://seekingalpha.com/currents/post/1441891\" target=\"_blank\">tax security gain</a>. This would put EPS at C$1.45 vs. expectations for C$1.58.</li>\n<li>KBW's <a href=\"http://watch.bnn.ca/#clip1053344\" target=\"_blank\">Brian Klock agrees</a>, and in fact strips out even more due to securities gains. He sees an operating number closer to $1.41, or a $0.17 miss. Particularly notable, says Klock, was a 10 basis point decline in net interest margin, and the big decline in U.S. banking profit (-28%).</li>\n<li>TD Bank (<a href=\"https://seekingalpha.com/symbol/TD\" title=\"Toronto-Dominion Bank\">TD</a> <font color=\"red\">-1.5%</font>), Scotiabank (<a href=\"https://seekingalpha.com/symbol/BNS\" title=\"The Bank of Nova Scotia\">BNS</a> <font color=\"red\">-1.9%</font>), CIBC (<a href=\"https://seekingalpha.com/symbol/CM\" title=\"Canadian Imperial Bank of Commerce\">CM</a> <font color=\"red\">-1.7%</font>), RBC (<a href=\"https://seekingalpha.com/symbol/RY\" title=\"Royal Bank of Canada\">RY</a> <font color=\"red\">-1.7%</font>).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442821\" data-linked=\"Canadian banks slip after BMO kicks off FQ4 earnings\" data-tweet=\"$BMO $BMO $TD - Canadian banks slip after BMO kicks off FQ4 earnings https://seekingalpha.com/news/1442821-canadian-banks-slip-after-bmo-kicks-off-fq4-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/1442821-canadian-banks-slip-after-bmo-kicks-off-fq4-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442791\" data-ts=\"1386087683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442791-tonix-pharma-trades-higher-again-article-sees-potential-for-big-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma trades higher again, article sees potential for big gains</a></h4><ul>\n<li>Shares of Tonix Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/TNXP\" title=\"Tonix Pharmaceuticals Holding Corp.\">TNXP</a> <font color=\"green\">+1%</font>)  are up again today after rising <font color=\"green\">8%</font> in Monday's session.</li>\n<li>Perhaps helping the cause is SA Pro's Joe Springer, whose <a href=\"https://seekingalpha.com/article/1870881-4-reasons-tonix-could-be-a-multi-bagger\" target=\"_blank\">bullish piece</a> came out of embargo today.</li>\n<li>Springer identifies what he calls the \"four most important trends and catalysts\" for the shares and says the stock \"could be a multi-bagger.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442791\" data-linked=\"Tonix Pharma trades higher again, article sees potential for big gains\" data-tweet=\"$TNXP - Tonix Pharma trades higher again, article sees potential for big gains https://seekingalpha.com/news/1442791-tonix-pharma-trades-higher-again-article-sees-potential-for-big-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/1442791-tonix-pharma-trades-higher-again-article-sees-potential-for-big-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442771\" data-ts=\"1386087037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAX\" target=\"_blank\">RAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442771-rackspace-tumbles-amazon-and-others-lower-following-google-cloud-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rackspace tumbles, Amazon and others lower following Google cloud launch</a></h4><ul>\n<li>Rackspace (<a href=\"https://seekingalpha.com/symbol/RAX\" title=\"Rackspace Hosting, Inc.\">RAX</a> <font color=\"red\">-5.9%</font>) is once more falling (<a href=\"https://seekingalpha.com/currents/post/1129462\" target=\"_blank\">previous</a>) due to a product announcement from a cloud infrastructure (IaaS) rival, only this time the culprit is Google (<a href=\"https://seekingalpha.com/symbol/GOOG\" title=\"Alphabet, Inc. Cl C\">GOOG</a> <font color=\"green\">+0.5%</font>) rather than Amazon (<a href=\"https://seekingalpha.com/symbol/AMZN\" title=\"Amazon.com, Inc.\">AMZN</a> <font color=\"red\">-1.8%</font>). The search giant has taken its Compute Engine IaaS platform <a href=\"https://seekingalpha.com/currents/post/1441521\" target=\"_blank\">out of beta</a>, and has cut computing and persistent storage prices by 10% and 60%, respectively.</li>\n<li>Amazon is also lower, as are Red Hat (<a href=\"https://seekingalpha.com/symbol/RHT\" title=\"Red Hat, Inc.\">RHT</a> <font color=\"red\">-1.3%</font>) and data center owner Equinix (<a href=\"https://seekingalpha.com/symbol/EQIX\" title=\"Equinix, Inc.\">EQIX</a> <font color=\"red\">-0.9%</font>). Like Racksapce, Red Hat is <a href=\"http://www.zdnet.com/red-hat-wants-to-be-openstacks-big-dog-7000022829/\" target=\"_blank\">a major supporter</a> of the OpenStack IaaS platform.</li>\n<li>In addition to cutting prices, Google has <a href=\"http://techcrunch.com/2013/12/02/googles-compute-engine-hits-general-availability-drops-instance-prices-10-adds-new-16-core-instance-types-and-docker-support/\" target=\"_blank\">greatly expanded</a> Compute Engine's feature set. The company has added support for more Linux variants (inc. Red Hat and rival distributions) and popular app deployment tool <a href=\"https://www.docker.io/\" target=\"_blank\">Docker</a>, and is launching a 16-core computing instance and high-I/O storage instances for intense workloads.</li>\n<li>Amazon, which <a href=\"https://seekingalpha.com/currents/post/1436121\" target=\"_blank\">just unveiled</a> several new cloud services, still has a big edge on Google in terms of scale, feature set, and developer support. But consulting firm Scalr declares Google <a href=\"http://blogs.wsj.com/digits/2013/12/03/google-wants-its-server-farm-to-be-as-fertile-as-amazons/\" target=\"_blank\">to be ahead</a> of Amazon in terms of performance and reliability. They're considered even on pricing.</li>\n<li>Moreover Google's IT and engineering resources, together with its expertise in creating cheap, high-performance, data center hardware, should make it a solid rival in time, at least for basic computing/storage services.</li>\n<li>\n<a href=\"https://seekingalpha.com/currents/post/1436111\" target=\"_blank\">Previous:</a> Amazon dominates cloud infrastructure</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442771\" data-linked=\"Rackspace tumbles, Amazon and others lower following Google cloud launch\" data-tweet=\"$RAX $RAX $GOOG - Rackspace tumbles, Amazon and others lower following Google cloud launch https://seekingalpha.com/news/1442771-rackspace-tumbles-amazon-and-others-lower-following-google-cloud-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/1442771-rackspace-tumbles-amazon-and-others-lower-following-google-cloud-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442751\" data-ts=\"1386086790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RSLS\" target=\"_blank\">RSLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442751-enteromedics-posts-big-gains-on-vbloc-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnteroMedics posts big gains on VBLOC data</a></h4><ul>\n<li>EnteroMedics (ETRM <font color=\"green\">+31.4%</font>) soars after announcing 18-month safety and efficacy results from ReCharge (pivotal <a href=\"https://seekingalpha.com/currents/search?query=VBLOC\" target=\"_blank\">VBLOC</a> study).</li>\n<li>Summary: Treatment group EWL, 25% and 10% TBL; control group, 12% EWL and 4% TBL.</li>\n<li>Results were statistically superior at p&lt;.0001.</li>\n<li>SAE rate at 18 months: 4.3% (12-month threshold was 15%).</li>\n<li>\"These study results, along with multi-year data from our earlier  clinical trials, demonstrate durability of effect and a superior record  of safety,\" CEO Mark Knudson says. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442751\" data-linked=\"EnteroMedics posts big gains on VBLOC data\" data-tweet=\"$RSLS - EnteroMedics posts big gains on VBLOC data https://seekingalpha.com/news/1442751-enteromedics-posts-big-gains-on-vbloc-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1442751-enteromedics-posts-big-gains-on-vbloc-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442741\" data-ts=\"1386086588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442741-arch-coal-plus-2_6-percent-on-proposed-financial-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Coal +2.6% on proposed financial changes</a></h4><ul>     <li>Arch Coal (<a href=\"https://seekingalpha.com/symbol/ACI\" title=\"Albertsons Companies Inc\">ACI</a> <font color=\"green\">+2.6%</font>) moves higher on its newly announced measures to improve its financial flexibility, including amending its senior secured  credit facility and reducing the facility's size to $250M from $350M.</li>     <li>ACI also plans to seek additional amendments to its credit facility to increase the amount of its term loan facility to $1.95B from $1.65B by adding an incremental $300M term loan B.</li>     <li>ACI also says it will sell $600M in senior notes due  in 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442741\" data-linked=\"Arch Coal +2.6% on proposed financial changes\" data-tweet=\"$ARCH - Arch Coal +2.6% on proposed financial changes https://seekingalpha.com/news/1442741-arch-coal-plus-2_6-percent-on-proposed-financial-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/1442741-arch-coal-plus-2_6-percent-on-proposed-financial-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442721\" data-ts=\"1386086275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442721-tesla-motors-roundup-shares-rally-model-s-safety-nod-vin-analysis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla Motors roundup: Shares rally, Model S safety nod, VIN analysis</a></h4><ul> <li>Shares of Tesla Motors (<a href=\"https://seekingalpha.com/symbol/TSLA\" title=\"Tesla, Inc.\">TSLA</a> <font color=\"green\">+11.4%</font>) hit their highest level since mid-November as a <a href=\"https://seekingalpha.com/currents/post/1441781\" target=\"_blank\">report</a> that the automaker has been cleared by German regulators on safety defects for the Model S improves sentiment.</li> <li>Analysts with Jefferies snuck a peek at some VIN numbers during visits to Tesla stores in California and walked away convinced that the company is on pace to meet its guidance for Q4 deliveries of 6K vehicles.</li> <li>Ground zero for the dissection of the VIN numbers used by Tesla is a <a href=\"http://www.teslamotors.com/forum/forums/new-vin-thread-please-post-your-newly-assigned-vins-here?page=20\" target=\"_blank\">thread</a> on the forums section of the Tesla website.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1442721\" data-linked=\"Tesla Motors roundup: Shares rally, Model S safety nod, VIN analysis\" data-tweet=\"$TSLA - Tesla Motors roundup: Shares rally, Model S safety nod, VIN analysis https://seekingalpha.com/news/1442721-tesla-motors-roundup-shares-rally-model-s-safety-nod-vin-analysis?source=tweet\" data-url=\"https://seekingalpha.com/news/1442721-tesla-motors-roundup-shares-rally-model-s-safety-nod-vin-analysis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442601\" data-ts=\"1386084482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442601-healthcare-initiations-for-tuesday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare initiations for Tuesday</a></h4><ul>\n<li>Galectin Therapeutics (<a href=\"https://seekingalpha.com/symbol/GALT\" title=\"Galectin Therapeutics, Inc.\">GALT</a> <font color=\"green\">+14.2%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8940886\" target=\"_blank\">initiated</a> at Buy at MLV. Price target is $20.</li>\n<li>Oramed Pharma (<a href=\"https://seekingalpha.com/symbol/ORMP\" title=\"Oramed Pharmaceuticals Inc.\">ORMP</a> <font color=\"green\">+3.6%</font>) <a href=\"http://www.streetinsider.com/Hot+New+Coverage/Aegis+Capital+Starts+Oramed+Pharma+%28ORMP%29+at+Buy%2C+PT+%2425/8942055.html\" target=\"_blank\">started</a> at Buy at Aegis. Price target is $25.</li>\n<li>Sorrento Therapeutics (<a href=\"https://seekingalpha.com/symbol/SRNE\" title=\"Sorrento Therapeutics, Inc.\">SRNE</a> <font color=\"green\">+2.6%</font>) <a href=\"http://www.streetinsider.com/Hot+New+Coverage/Aegis+Capital+Starts+Sorrento+Therapeutics+%28SRNE%29+at+Buy%2C+PT+%2440/8942028.html\" target=\"_blank\">started</a> at Buy at Aegis. Price target is $40.</li>\n<li>Team Health (<a href=\"https://seekingalpha.com/symbol/TMH\" title=\"Team Health Holdings, Inc.\">TMH</a> <font color=\"green\">+0.4%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8940846\" target=\"_blank\">initiated</a> at Buy at SunTrust. Price target is $54.</li>\n<li>IPC (<a href=\"https://seekingalpha.com/symbol/IPCM\" title=\"IPC The Hospitalist Company, Inc.\">IPCM</a> <font color=\"green\">+0.1%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8940850\" target=\"_blank\">started</a> at Neutral at SunTrust. Price target is $63.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442601\" data-linked=\"Healthcare initiations for Tuesday\" data-tweet=\"$GALT $GALT $ORMP - Healthcare initiations for Tuesday https://seekingalpha.com/news/1442601-healthcare-initiations-for-tuesday?source=tweet\" data-url=\"https://seekingalpha.com/news/1442601-healthcare-initiations-for-tuesday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442551\" data-ts=\"1386083938\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRI\" target=\"_blank\">AMRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442551-albany-molecular-research-sells-off-on-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albany Molecular Research sells-off on downgrade</a></h4><ul>\n<li>Albany Molecular Research (<a href=\"https://seekingalpha.com/symbol/AMRI\" title=\"Albany Molecular Research, Inc.\">AMRI</a> <font color=\"red\">-10%</font>) slides hard in morning trading.</li>\n<li>Sterne Agee has <a href=\"http://www.streetinsider.com/Analyst+PT+Change/Sterne+Agee+Downgrades+Albany+Molecular+Research+%28AMRI%29+to+Neutral/8940895.html\" target=\"_blank\">cut</a> the shares to Neutral from Buy.</li>\n<li>Price target is now $12 (from $15).</li>\n<li>Here's analyst Greg Bolan: \"As we have written multiple times, we believe CRO valuations <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4124091/update-sterne-agee-downgrades-albany-molecular-research-\" target=\"_blank\">are  expensive</a> and therefore have a difficult time seeing AMRI generate a  strong return through acquisition(s).\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442551\" data-linked=\"Albany Molecular Research sells-off on downgrade\" data-tweet=\"$AMRI - Albany Molecular Research sells-off on downgrade https://seekingalpha.com/news/1442551-albany-molecular-research-sells-off-on-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1442551-albany-molecular-research-sells-off-on-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442501\" data-ts=\"1386083276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AT\" target=\"_blank\">AT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442501-atlantic-power-downgraded-by-bmo-shares-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlantic Power downgraded by BMO, shares fall</a></h4><ul>\n<li>Shares of Atlantic Power (<a href=\"https://seekingalpha.com/symbol/AT\" title=\"Atlantic Power Corporation\">AT</a> <font color=\"red\">-6.1%</font>) are notably lower in morning trading.</li>\n<li>BMO has <a href=\"http://www.streetinsider.com/Analyst+PT+Change/BMO+Capital+Downgrades+Atlantic+Power+%28AT%29+to+Underperform/8940834.html\" target=\"_blank\">cut</a> the stock to Underperform.</li>\n<li>Price target now $3.05 (from $4.29).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442501\" data-linked=\"Atlantic Power downgraded by BMO, shares fall\" data-tweet=\"$AT - Atlantic Power downgraded by BMO, shares fall https://seekingalpha.com/news/1442501-atlantic-power-downgraded-by-bmo-shares-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/1442501-atlantic-power-downgraded-by-bmo-shares-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442401\" data-ts=\"1386082368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442401-myriad-genetics-falls-again-as-jmp-says-reimbursement-pricing-may-not-be-error\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad Genetics falls again as JMP says reimbursement pricing may not be error</a></h4><ul>\n<li>Shares of Myriad Genetics (<a href=\"https://seekingalpha.com/symbol/MYGN\" title=\"Myriad Genetics, Inc.\">MYGN</a> <font color=\"red\">-7.7%</font>) trade sharply lower out of the gate on the heels of a big decline Monday.</li>\n<li>There has been some confusion regarding whether a clerical error caused the BRCA1/2 full sequence to be <a href=\"https://seekingalpha.com/currents/post/1439911\" target=\"_blank\">priced the same</a> as a single gene BRCA1 test (Excel sheet can be obtained <a href=\"http://www.cms.gov/apps/ama/license.asp?file=/ClinicalLabFeeSched/downloads/14CLAB.zip\" target=\"_blank\">here</a>) on the 2014 fee schedule.</li>\n<li>Here's JMP <a href=\"https://twitter.com/zbiotech/status/407853699315146752/photo/1\" target=\"_blank\">on the issue</a>: \"Management maintains that this was another clerical error,\" but after reaching out to \"a half dozen of our lab manager contacts, as well as some reimbursement managers at a few private companies ... most believe that this is not a mistake on CMS's part but rather a reflection of how CMS is re-evaluating the calculus behind reimbursement levels for molecular tests.\"</li>\n<li>A bit more color: \"If it is an error, there is unlikely to be a fix in place by January 1.\"</li>\n<li>MYGN downgraded to Market Perform.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442401\" data-linked=\"Myriad Genetics falls again as JMP says reimbursement pricing may not be error\" data-tweet=\"$MYGN - Myriad Genetics falls again as JMP says reimbursement pricing may not be error https://seekingalpha.com/news/1442401-myriad-genetics-falls-again-as-jmp-says-reimbursement-pricing-may-not-be-error?source=tweet\" data-url=\"https://seekingalpha.com/news/1442401-myriad-genetics-falls-again-as-jmp-says-reimbursement-pricing-may-not-be-error\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442371\" data-ts=\"1386081903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIO\" target=\"_blank\">FIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442371-a-roundup-of-tech-ratings-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A roundup of tech ratings changes</a></h4><ul><li>Fusion-io (<a href='https://seekingalpha.com/symbol/FIO' title='Fusion-io, Inc.'>FIO</a> <font color='red'>-6.4%</font>) has been cut to Neutral by UBS.</li><li>Flir Systems (<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a> <font color='green'>+1.9%</font>), Verint (<a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color='green'>+1.8%</font>), and CACI (<a href='https://seekingalpha.com/symbol/CACI' title='CACI International Inc'>CACI</a> <font color='green'>+1.5%</font>) have been upgraded to Buy by CRT Capital.</li><li>Korea Telecom (<a href='https://seekingalpha.com/symbol/KT' title='KT Corporation'>KT</a> <font color='red'>-1.5%</font>) has been cut to Neutral by HSBC.</li><li>VOXX International (<a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='red'>-4.7%</font>) has been started at Outperform by Cowen.</li></ul><div class=\"tiny-share-widget\" data-id=\"1442371\" data-linked=\"A roundup of tech ratings changes\" data-tweet=\"$FIO $FIO $FLIR - A roundup of tech ratings changes https://seekingalpha.com/news/1442371-a-roundup-of-tech-ratings-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/1442371-a-roundup-of-tech-ratings-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442361\" data-ts=\"1386081388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442361-thai-shares-rally-as-police-ordered-not-to-confront-protesters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thai shares rally as police ordered not to confront protesters</a></h4><ul><li>Thai shares (<a href='https://seekingalpha.com/symbol/thd' title='iShares MSCI Thailand Capped ETF'>THD</a>, <a href='https://seekingalpha.com/symbol/ttf' title='Thai Fund'>TTF</a>, <a href='https://seekingalpha.com/symbol/tf' title='Thai Capital Fund'>TF</a>) rise <font color='green'>0.7% </font>in Bangkok. Investors are hopeful that a move by Yingluck Shinawatra to <a href=\"http://www.theguardian.com/world/2013/dec/02/thailand-yingluck-shinawatra-talks-resignation-bring-peace\" target=\"_blank\">allow demonstrators</a> to reach government buildings will ease tensions.</li><li>Elsewhere in the region, Indonesian (<a href='https://seekingalpha.com/symbol/idx' title='Market Vectors Indonesia Index ETF'>IDX</a>, <a href='https://seekingalpha.com/symbol/idxj' title='Market Vectors Indonesia Small Cap ETF'>IDXJ</a>, <a href='https://seekingalpha.com/symbol/eido' title='iShares MSCI Indonesia ETF'>EIDO</a>) and Philippine (<a href='https://seekingalpha.com/symbol/ephe' title='iShares MSCI Philippines ETF'>EPHE</a>) shares fall <font color='red'>0.8%</font> and <font color='red'>0.7%</font> respectively.</li></ul><div class=\"tiny-share-widget\" data-id=\"1442361\" data-linked=\"Thai shares rally as police ordered not to confront protesters\" data-tweet=\"$THD $TTF $TF-OLD - Thai shares rally as police ordered not to confront protesters https://seekingalpha.com/news/1442361-thai-shares-rally-as-police-ordered-not-to-confront-protesters?source=tweet\" data-url=\"https://seekingalpha.com/news/1442361-thai-shares-rally-as-police-ordered-not-to-confront-protesters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442331\" data-ts=\"1386081165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRPN\" target=\"_blank\">GRPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442331-groupon-reports-strong-weekend-sales-shares-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Groupon reports strong weekend sales, shares rally</a></h4><ul>\n<li>Groupon (<a href=\"https://seekingalpha.com/symbol/GRPN\" title=\"Groupon, Inc.\">GRPN</a> <font color=\"green\">+3.7%</font>) reports its North American billings for the four-day Thanksgiving weekend were up 30% Y/Y.  The company adds 55% of those transactions took place via mobile devices. (PR)</li>\n<li>The billings growth rate is soundly above the 20% North American gross billings growth Groupon reported for Q3, and even with the 30% clip it reported for Q2. The share of N.A. transactions coming via mobile appears to be up slightly from Q3, during which time mobile accounted for \"over 50%\" of buying activity.</li>\n<li>Amazon and eBay <a href=\"https://seekingalpha.com/currents/post/1438701\" target=\"_blank\">also saw</a> strong weekend sales.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442331\" data-linked=\"Groupon reports strong weekend sales, shares rally\" data-tweet=\"$GRPN - Groupon reports strong weekend sales, shares rally https://seekingalpha.com/news/1442331-groupon-reports-strong-weekend-sales-shares-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/1442331-groupon-reports-strong-weekend-sales-shares-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442321\" data-ts=\"1386080930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MFIN\" target=\"_blank\">MFIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442321-medallion-financial-tumbles-8-percent-after-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medallion Financial tumbles 8% after secondary</a></h4><ul>\n<li>\n<em>It was raining hard in 'Frisco</em> ... TAXI is <font color=\"red\">off 8.5%</font> premarket to $16.10 after pricing a 2.9M share secondary at $16.40. The underwriter greenshoe is for an additional 435K shares. The offering will add about 15% to the float.</li>\n<li>Net proceeds of about $45.16M are expected.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442321\" data-linked=\"Medallion Financial tumbles 8% after secondary\" data-tweet=\"$MFIN - Medallion Financial tumbles 8% after secondary https://seekingalpha.com/news/1442321-medallion-financial-tumbles-8-percent-after-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/1442321-medallion-financial-tumbles-8-percent-after-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442131\" data-ts=\"1386079156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STML\" target=\"_blank\">STML</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442131-feuerstein-questions-stemlines-use-of-message-board-posts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Feuerstein questions Stemline&#39;s use of message board posts</a></h4><ul>\n<li>Shares of Stemline Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/STML\" title=\"Stemline Therapeutics\">STML</a>) are off <font color=\"red\">4%</font> in premarket trading in the face of a <a href=\"http://www.thestreet.com/story/12133245/1/stemline-cribs-cancer-patient-message-boards-to-promote-stock.html\" target=\"_blank\">rather negative article</a> by <em>TheStreet</em>'s Adam Feuerstein.</li>\n<li>Feuerstein discusses the company's use of posts from a message board (hosted by the Leukemia and Lymphoma Society) in its investor slide deck.</li>\n<li>The article questions the appropriateness of leaving out certain passages of the posts when using them in the investor presentation.</li>\n<li>Feuerstein also says \"a donor lymphocyte infusion\" may have contributed to the complete remission of one patient being treated with SL-401, a possibility the company acknowledged as \"within the realm of possibility.\"</li>\n<li>For more on <a href=\"https://seekingalpha.com/currents/search?query=SL-401\" target=\"_blank\">SL-401</a>, see here.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442131\" data-linked=\"Feuerstein questions Stemline&#39;s use of message board posts\" data-tweet=\"$STML - Feuerstein questions Stemline&#39;s use of message board posts https://seekingalpha.com/news/1442131-feuerstein-questions-stemlines-use-of-message-board-posts?source=tweet\" data-url=\"https://seekingalpha.com/news/1442131-feuerstein-questions-stemlines-use-of-message-board-posts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442011\" data-ts=\"1386077632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTL\" target=\"_blank\">MTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442011-mechel-reaches-agreement-extending-grace-period-maturity-in-1b-loan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mechel reaches agreement extending grace period, maturity in $1B loan</a></h4><ul>\n<li>Mechel (NYSE:<a href=\"https://seekingalpha.com/symbol/MTL\" title=\"Mechel OAO\">MTL</a>) <font color=\"green\">+8.6%</font> premarket after announcing an agreement to extend the grace period and maturity of its $1B syndicated facility to the end of 2014 and 2016, respectively.</li>\n<li>MTL says the agreement will ensure a more stable financial environment and greatly ease the pressure on cash flow in the next 12 months at the Russian mining company, moving ~$600M of repayments from 2013-2014 to 2015-2016.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1442011\" data-linked=\"Mechel reaches agreement extending grace period, maturity in $1B loan\" data-tweet=\"$MTL - Mechel reaches agreement extending grace period, maturity in $1B loan https://seekingalpha.com/news/1442011-mechel-reaches-agreement-extending-grace-period-maturity-in-1b-loan?source=tweet\" data-url=\"https://seekingalpha.com/news/1442011-mechel-reaches-agreement-extending-grace-period-maturity-in-1b-loan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1442001\" data-ts=\"1386077461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/V\" target=\"_blank\">V</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1442001-visa-lower-on-reports-of-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Visa lower on reports of share offering</a></h4><ul> <li>Shares of Visa (NYSE:<a href=\"https://seekingalpha.com/symbol/V\" title=\"Visa Inc.\">V</a>) dip in premarket trading on <a href=\"http://www.streetinsider.com/Equity+Offerings/Visa+%28V%29+Said+to+Offer+8M+Shares+Via+JPMorgan/8941291.html\" target=\"_blank\">reports</a> that the company will offer 8M shares in a new offering.</li>  <li>V <font color=\"red\">-2.4%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1442001\" data-linked=\"Visa lower on reports of share offering\" data-tweet=\"$V - Visa lower on reports of share offering https://seekingalpha.com/news/1442001-visa-lower-on-reports-of-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/1442001-visa-lower-on-reports-of-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1441981\" data-ts=\"1386077262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECTE\" target=\"_blank\">ECTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1441981-echo-therapeutics-to-offer-shares-warrants\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Echo Therapeutics to offer shares, warrants</a></h4><ul>\n<li>Echo Therapeutics (<a href=\"https://seekingalpha.com/symbol/ECTE\" title=\"Echo Therapeutics\">OTC:ECTE</a>) dips <font color=\"red\">6.5%</font> premarket.</li>\n<li>The company is \"offering 3,225,806 units\" consisting of one share of common and a warrant.</li>\n<li>The warrants are exercisable immediately. (<a href=\"http://www.sec.gov/Archives/edgar/data/1031927/000141588913002481/ectes1nov2013.htm\" target=\"_blank\">S-1</a>)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1441981\" data-linked=\"Echo Therapeutics to offer shares, warrants\" data-tweet=\"$ECTE - Echo Therapeutics to offer shares, warrants https://seekingalpha.com/news/1441981-echo-therapeutics-to-offer-shares-warrants?source=tweet\" data-url=\"https://seekingalpha.com/news/1441981-echo-therapeutics-to-offer-shares-warrants\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1441961\" data-ts=\"1386076813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNAT\" target=\"_blank\">CNAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1441961-conatus-pharma-jumps-on-orphan-designation-for-caspase-protease-inhibitor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conatus Pharma jumps on Orphan designation for caspase protease inhibitor</a></h4><ul>\n<li>Conatus Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CNAT\" title=\"Conatus Pharmaceuticals\">CNAT</a>) rallies <font color=\"green\">31%</font> before the bell.<br>\n</li>\n<li>The FDA has granted emricasan an Orphan Designation for \"the treatment of liver transplant recipients with reestablished fibrosis  to delay the progression to cirrhosis and end-stage liver disease.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1441961\" data-linked=\"Conatus Pharma jumps on Orphan designation for caspase protease inhibitor\" data-tweet=\"$CNAT - Conatus Pharma jumps on Orphan designation for caspase protease inhibitor https://seekingalpha.com/news/1441961-conatus-pharma-jumps-on-orphan-designation-for-caspase-protease-inhibitor?source=tweet\" data-url=\"https://seekingalpha.com/news/1441961-conatus-pharma-jumps-on-orphan-designation-for-caspase-protease-inhibitor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1441941\" data-ts=\"1386076530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1441941-lexicon-pharmaceuticals-falls-on-lx1033-top-line-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lexicon Pharmaceuticals falls on LX1033 top-line data</a></h4><ul>\n<li>Lexicon Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/LXRX\" title=\"Lexicon Pharmaceuticals, Inc.\">LXRX</a>) slides <font color=\"red\">11%</font> in premarket trading.</li>\n<li>Although top-line results from a Phase 2 study of LX1033 in IBS-d showed patients experienced \"significant improvements over time,\" the company says  \"differences between placebo and LX1033 in stool consistency were not statistically significant.\"</li>\n<li>Here's CMO Pablo Lapuerta: \"While this initial Phase 2a study was underway, we completed long-term  toxicology studies which would allow us to conduct a Phase 2b study at  doses informed by the current results and with a duration of 12 weeks.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1441941\" data-linked=\"Lexicon Pharmaceuticals falls on LX1033 top-line data\" data-tweet=\"$LXRX - Lexicon Pharmaceuticals falls on LX1033 top-line data https://seekingalpha.com/news/1441941-lexicon-pharmaceuticals-falls-on-lx1033-top-line-data?source=tweet\" data-url=\"https://seekingalpha.com/news/1441941-lexicon-pharmaceuticals-falls-on-lx1033-top-line-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1441881\" data-ts=\"1386075729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMED\" target=\"_blank\">OMED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1441881-oncomed-soars-on-demcizumab-deal-with-celgene\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoMed soars on demcizumab deal with Celgene</a></h4><ul>\n<li>OncoMed Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OMED\" title=\"OncoMed Pharmaceuticals, Inc\">OMED</a>) announces a development and commercialization agreement with Celgene (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CELG\" title=\"Celgene Corporation\">CELG</a>).<br>\n</li>\n<li>The deal includes demcizumab and \"up to six anti-cancer stem cell product candidates.\"</li>\n<li>OMED gets $177.25M upfront ($22.25M equity investment).</li>\n<li>OMED also keeps \"global co-development and U.S. co-commercialization rights for five of  the six anti-CSC product candidates with 50/50 U.S. profit sharing, and  royalties to be received in other territories.\"</li>\n<li>CELG has an exclusive option on demcizumab subsequent to which OMED will \"co-develop [the drug and] share global development costs on a 1/3 OMED and 2/3 CELG basis.\" (PR)</li>\n<li>OMED <strong><font color=\"green\">+60%</font></strong> premarket.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1441881\" data-linked=\"OncoMed soars on demcizumab deal with Celgene\" data-tweet=\"$OMED $OMED $CELG - OncoMed soars on demcizumab deal with Celgene https://seekingalpha.com/news/1441881-oncomed-soars-on-demcizumab-deal-with-celgene?source=tweet\" data-url=\"https://seekingalpha.com/news/1441881-oncomed-soars-on-demcizumab-deal-with-celgene\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1441571\" data-ts=\"1386066428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1441571-world-stocks-fall-on-apprehension-about-fed-tapering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">World stocks fall on apprehension about Fed tapering</a></h4><ul>   <li>Global equities are mostly lower, with <a href=\"http://www.reuters.com/article/2013/12/03/markets-europe-stocks-open-idUSL5N0JI17L20131203\" target=\"_blank\">fears of the taper</a> being cited as the reason following decent U.S. economic data yesterday.</li>    <li>However, not everyone's buying thesis. \"Speculation that the Fed could start trimming its stimulus in December shouldn't stress equities excessively,\" says UniCredit strategist Christian Stocker. The economy is recovering, which \"is a prerequisite for further gains in equities.\"</li>        <li>Chinese shares buck the trend and <font color=\"green\">rise 0.7%, </font>helped by a drop in money-market rates, which eases concerns of a cash squeeze. The Nikkei also closes up, apparently boosted by a weaker yen.</li>\n<li>Japan <font color=\"green\">+0.6%</font>, Hong Kong <font color=\"red\">-0.5%</font>, India <font color=\"red\">-0.2%</font>.</li>\n<li>London <font color=\"red\">-0.6%</font>, Paris <font color=\"red\">-1.4%</font>, Frankfurt <font color=\"red\">-0.8%</font>.</li>\n<li>U.S. stock futures: Dow <font color=\"red\">-0.2%</font>, S&amp;P <font color=\"red\">-0.2%</font>, Nasdaq flat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1441571\" data-linked=\"World stocks fall on apprehension about Fed tapering\" data-tweet=\"World stocks fall on apprehension about Fed tapering https://seekingalpha.com/news/1441571-world-stocks-fall-on-apprehension-about-fed-tapering?source=tweet\" data-url=\"https://seekingalpha.com/news/1441571-world-stocks-fall-on-apprehension-about-fed-tapering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1576818000,"end":1576904399,"str":"Friday, December 20, 2019"},"yesterday":{"start":1576731600,"end":1576817999}}